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Abstract Peroxynitrite at low concentrations (3^10 WM)
inhibited agonist-induced platelet aggregation by a mechanism
not dependent on the formation of cyclic guanosine mono-
phosphate. Platelets recovered completely from peroxynitrite-
induced inhibition within 30 min. Peroxynitrite induced nitration
of cytosolic proteins, but this diminished to near basal levels
within 60 min of exposure to the oxidant. During this period
there was a reduction in tyrosine phosphorylation of specific
proteins such as syk, but this was not due to direct nitration of
these same proteins. The inhibition of phosphorylation was
reversible with platelet proteins recovering the ability to be
phosphorylated within 15 min of exposure to peroxynitrite.
Conversely, peroxynitrite increased phosphorylation of other
proteins, but again these events were not directly linked to
nitration. Nitration may affect the phosphorylation of tyrosine
residues in a number of proteins, but by an indirect route,
possibly by acting on proteins upstream in the signalling
cascades. We suggest that low concentrations of peroxynitrite
reversibly inhibit platelet aggregation by preventing the phos-
phorylation of key signalling proteins. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Platelet aggregation, induced by speci¢c agonists, is the
culmination of several exquisitely integrated signalling path-
ways, which lead to biochemical and morphological changes
in the cell. Excessive platelet activation is limited by the en-
dothelial-derived platelet inhibitors prostacyclin (PGI2) and
nitric oxide (NO) [1]. NO, unlike PGI2, is able to inhibit
both platelet activation and adhesion to the subendothelium.
NO, which activates soluble guanylyl cyclase (sGC) leading to
the formation of cyclic guanosine monophosphate (cGMP),
inhibits platelet activation by reducing the intracellular calci-
um concentration through the action of cGMP-dependent ki-
nases [2]. The regulation of platelet activity by NO is crucial
in preventing excessive platelet aggregation and thrombi.
NO undergoes a di¡usion limited reaction with superoxide
anion (O32 ) to form peroxynitrous acid (ONOOH), a potent
oxidant [3] which has been shown to be released by endothe-
lial cells [4]. This can lead to a reduction in the bioavailability
of NO at the endothelial surface, and possibly to a loss of
platelet regulation. The in£uence of peroxynitrite on platelet
function has been shown to be concentration-dependent. At
high concentrations, in excess of 150 WM, peroxynitrite acts as
a platelet agonist by stimulating aggregation [5]. At lower
concentrations or in the presence of plasma, peroxynitrite
acts as a platelet inhibitor, although much less e¡ectively
than NO [5^7]. The mechanism of this inhibition has been
proposed to be cGMP-dependent [5,6] since peroxynitrite ni-
trosates thiol-containing proteins, though ine⁄ciently, to form
nitrosothiols [8]. The nitrosothiols then inhibit platelets
through the release of NO. However, peroxynitrite also under-
goes a range of di¡erent reactions at physiological pH, which
may a¡ect cell function. Peroxynitrite nitrates phenols such as
tyrosine [9], accounting for the presence of nitrated proteins in
normal plasma [10]. The presence of nitrated proteins has
been used as a marker for peroxynitrite formation in tissues,
while the formation of nitrotyrosine intracellularly may have
important consequences for cell function. Peroxynitrite-in-
duced nitration of peptides has been shown to reduce their
phosphorylation when exposed to speci¢c protein kinases
[11,12], suggesting that protein nitration may interfere with
protein phosphorylation signalling pathways. Furthermore,
we have recently shown that nitrated proteins form sponta-
neously in platelets undergoing collagen-induced aggregation
[13]. The function of these nitrated proteins is unknown.
In the present study, we examined the e¡ects of peroxyni-
trite on platelet function with the aim of dissecting the relative
contributions of the NO-cGMP pathway and protein nitra-
tion. Our data indicate that peroxynitrite inhibits platelet ag-
gregation in a cGMP-independent and reversible manner, and
that the major action of peroxynitrite is to prevent, reversibly,
the agonist-induced phosphorylation of signalling proteins.
2. Materials and methods
Prostacyclin (synthetic sodium salt), thrombin (human), bovine se-
rum albumin (BSA), trichloroacetic acid (TCA) and (3-[3-cholamido-
propyl]dimethylammonio)-1-propane-sulphonate (CHAPS) bu¡er
were purchased from Sigma Chemical Co. (Poole, UK), collagen
Type I (equine) from Hormonchemie (Munich, Germany) and ODQ
from Tocris-Cookson Chemicals (Southampton, UK).
Biotinylated goat anti-rabbit IgG and horseradish peroxidase
(HRP)-linked anti-rabbit IgG antibodies and nitrocellulose (pore
size 0.45Wm) were obtained from Amersham Pharmacia Biotech
(Bucks, UK). Avidin^biotin HRP was from DAKO Ltd. (Beacons-
¢eld, UK). Polyclonal anti-nitrotyrosine antibody was produced in
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our laboratory, while anti-phosphotyrosine HRP-linked (PY-20) anti-
body was from Santa Cruz (Insight Biotechnology Ltd., Middlesex,
UK), anti-syk monoclonal antibody and rabbit anti-nitrotyrosine
polyclonal antibody were from Upstate Biotechnology (TCS Biolog-
icals, Bucks, UK). Pre-cast NuPAGE 10% and 4^12% gradient gels
and NuPAGE sample bu¡er were purchased from Invitrogen Life
Technologies (Paisley, UK). Enhanced chemoluminescence (ECL) re-
agents were obtained from Perbio (Cheshire, UK). The cGMP ELISA
kits were purchased form Cayman Chemicals (USA).
2.1. Platelet preparations
Venous blood was taken with informed consent from healthy vol-
unteers, who denied taking any medication in the previous 14 days,
placed into acid^citrate^dextrose anti-coagulant and centrifuged for
20 min at 150Ug to yield platelet-rich plasma (PRP). Washed plate-
lets (WPs) were prepared from PRP in the presence of prostacyclin as
described elsewhere [14], suspended in bu¡er (NaCl 137 mM,
NaH2PO4 4.2 mM, NaHCO3 11.9 mM, KCl 2.7 mM, pH 7.4) and
diluted to a count of 3U108 platelets/ml. The platelets were rested for
1 h at room temperature and used within the next 2 h.
To prepare cytosolic and membrane fractions, WPs were sonicated
at 4‡C (Soniprep, M.S.E., UK) for 2U15 s bursts separated by a
15 s pause, and the cytosol separated from the membrane fractions
by centrifugation at 1500Ug for 10 min. The pellet, which con-
tained the membrane fraction, was solubilised in 0.1% CHAPS bu¡er
[15].
2.2. Preparation of peroxynitrite
Sodium peroxynitrite was prepared using the acidi¢ed nitrite meth-
od [16]; controls were prepared by the same procedure, except that
the solutions were passed directly into water instead of NaOH, lead-
ing to immediate decomposition of the oxidant. NaOH was then
added to restore the pH to 10. Residual H2O2 was removed by pass-
ing the peroxynitrite through a MnO2 column and checked by absor-
bance at 220 nm. The concentration of stock peroxynitrite solutions
was determined spectrophotometrically (302 nm = 1670 M31 cm31)
[17] using decomposed peroxynitrite as the blank. Working dilutions
of both active and decomposed peroxynitrite were prepared in the
same manner using 1 mM NaOH.
2.3. Measurement of cGMP concentrations
WPs were pre-incubated with isobutylmethylxanthine (200 WM) for
30 min prior to experimentation. WPs were then incubated with either
peroxynitrite or NO and after 1 min the reactions halted by the
addition of TCA (5%). The cGMP was extracted with diethylether,
with the ether subsequently removed by heating extracted samples to
70‡C for 5 min. The cGMP was then analysed using a commercially
available ELISA kit.
2.4. Quanti¢cation of nitrated proteins
The nitrotyrosine content of proteins in the platelet samples was
estimated using a competitive semi-quantitative ELISA developed in
this laboratory [10]. The assay used nitrated BSA (NT-BSA) as a
standard and a commercially available rabbit anti-human polyclonal
anti-nitrotyrosine antibody. The amount of nitrotyrosine present after
peroxynitrite treatment of BSA was determined by absorbance at 438
nm (pH 9) using the molar extinction coe⁄cient of 4300 M31 cm31.
The molar ratio of nitrotyrosine to albumin was within 3^6 mol nitro-
tyrosine/mol protein. The results were extrapolated from a semi-log
plot of the standard curve and were expressed as nmol of NT-BSA
equivalents/mg of protein. The protein concentrations were estab-
lished using a modi¢ed Lowry method [18].
2.5. Sodium dodecyl sulphate^polyacrylamide gel electrophoresis
(SDS^PAGE) and immunoblotting
After various treatments, the reactions were stopped by addition of
NuPAGE sample bu¡er. Proteins were separated by SDS^PAGE on
either NuPAGE Bis^Tris 10% or 4^12% gradient gels. The separated
proteins were transferred to nitrocellulose membranes using wet trans-
fer techniques. Membranes were blocked with BSA (0.5%), dissolved
in PBS containing 1% PVP-10, 1% PEG, 0.2% Tween and 10 mM
NaF, for 60 min. Membranes were probed with anti-nitrotyrosine
(1:500), anti-phosphotyrosine (1:5000) or anti-syk (1:2500) for 60
min. The membranes were washed several times with PBS/Tween
0.05%, followed by incubation with HRP-linked goat anti-rabbit
IgG for 60 min. The protein bands were visualised using ECL re-
agents.
The in house polyclonal anti-nitrotyrosine antibody was raised
against nitrated Keyhole Limpet Hemocyanin and puri¢ed using stan-
dard a⁄nity puri¢cation techniques. Extensive characterisation was
performed using nitrated peptides and a variety of tyrosine deriva-
tives. The performance of this antibody in our ELISA was very sim-
ilar to the commercial polyclonal antibody, but gave clearer resolution
on immunoblots. The selectivity of the antibody was checked by treat-
ment of nitrated proteins with the reductant dithionite and by its
di¡erential recognition of peptides containing tyrosine, aminotyrosine
and nitrotyrosine.
2.6. Statistical analysis
All data are presented as the mean þ S.E.M. of at least three inde-
pendent experiments, unless otherwise stated. Statistical analysis was
performed using Student’s unpaired t-test.
3. Results
3.1. The in£uence of peroxynitrite on platelet aggregation
Incubation of WPs with peroxynitrite for 1 min prior to the
addition of thrombin (0.02 U/ml) led to the inhibition of
platelet aggregation compared to agonist alone (Table 1).
The e¡ect of peroxynitrite was concentration-dependent,
with the IC50 value established at 4.6 þ 0.9 WM. In control
experiments, decomposed peroxynitrite failed to inhibit
thrombin-induced platelet activation.
In order to ascertain whether peroxynitrite-mediated inhi-
bition of platelet aggregation was NO and cGMP-dependent,
the experiments were repeated in the presence of ODQ (10
WM), an inhibitor of sGC [19] and, therefore, of the conven-
tional NO-mediated pathway. The presence of ODQ did not
in£uence the inhibition of thrombin-induced platelet aggrega-
tion by peroxynitrite (Table 1a). It was also established that
Table 1
The in£uence of peroxynitrite on platelet aggregation and cGMP
formation
a: Peroxynitrite (WM) Inhibition of aggregation (%)
without ODQ with ODQ
0.01 4.5 þ 2.5 6.5 þ 6.5
0.1 17.5 þ 6.7 23.4 þ 8.9
1 ND 37.3 þ 7.2
10 67.6 þ 9.3 68.2 þ 17.2
100 98.2 þ 0.2 98.6 þ 1.4
Decomposed (10 WM) 0 0
b: Peroxynitrite (WM) cGMP (pmol 1U108 platelets)
without ODQ with ODQ
0 0.31 þ 0.12 0.09 þ 0.06
0.3 0.34 þ 0.17 0.06 þ 0.02
3 0.62 þ 0.29 0.21 þ 0.13
30 1.18 þ 0.27** 0.34 þ 0.11
Decomposed (10 WM) 0.27 þ 0.09 0.12 þ 0.07
Peroxynitrite (0^100 WM) was incubated with platelets for 1 min be-
fore the addition of thrombin (0.02 U/ml) and aggregation mea-
sured 3 min later. For cGMP measurement, platelets were pre-incu-
bated with isobutylmethylxanthine (200 WM) for 30 min prior to
addition of peroxynitrite. The reaction was halted after a 1 min in-
cubation with peroxynitrite by the addition of ice-cold TCA (5%).
The cGMP was extracted using diethyl and measured using a com-
petitive enzyme immunoassay. The results are expressed as pmol
cGMP/1U108 platelets. In some experiments the platelets were pre-
incubated with ODQ (10 WM) for 15 min before the addition of
peroxynitrite. Results for both inhibition of aggregation (n = 5) and
cGMP (n = 4) are expressed as mean þ S.E.M. **Ps 0.01 compared
to basal.
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the inhibitory action of ODQ on GC activity was not changed
by exposure to the peroxynitrite. ODQ was exposed to per-
oxynitrite (10 WM) prior to addition to platelets and still
shown to inhibit the action of NO on platelets (results not
shown). These results indicate that peroxynitrite acts primarily
through a mechanism independent of cGMP.
In a second series of experiments, we investigated whether
the e¡ects of peroxynitrite on platelets were reversible. Plate-
lets were incubated with peroxynitrite for up to 1 h before
stimulation with thrombin (0.02 U/ml). Incubation of peroxy-
nitrite (5 WM) for 1 min resulted in 60.7 þ 9.3% inhibition of
thrombin-stimulated aggregation. After a 15 min incubation,
the level of inhibition had declined to 14.9 þ 4.7% and at 30
min, no inhibition was evident (Fig. 1). These data suggest
that the actions of peroxynitrite are transient and non-toxic,
since it does not permanently impair the ability of platelets to
respond to thrombin. Similar data were obtained using colla-
gen as an agonist (data not shown).
3.2. cGMP synthesis in response to peroxynitrite and NO
The results of the aggregation experiments suggested that
the e¡ects of peroxynitrite were independent of both NO and
cGMP. To con¢rm this, the ability of peroxynitrite to induce
cGMP formation was assessed, and compared with that of
authentic NO solutions. When this oxidant was added to
platelets as a bolus and incubated at 37‡C for 1 min, peroxy-
nitrite caused a concentration-dependent increase in the for-
mation of cGMP from the basal level. However, this increase
was only signi¢cant at the highest concentration of peroxyni-
trite used (30 WM) which elevated cGMP from a basal level of
0.31 þ 0.12 to 1.18 þ 0.27 pmol/1U108 platelets (P6 0.01) (Ta-
ble 1); 0.3 and 3 WM peroxynitrite had no signi¢cant e¡ect on
basal levels. The presence of ODQ (10 WM) prevented the rise
of cGMP above basal levels with all concentrations of per-
oxynitrite (Table 1b). The rates of cGMP synthesis were much
lower than those measured for NO (1 WM NO produces
4.1 þ 0.6 pmol cGMP/108 platelets after 1 min). The inhibition
of platelet aggregation by peroxynitrite at 3^5 WM (the ap-
proximate IC50) does not appear to be due to increases in
cGMP formation.
3.3. Peroxynitrite-induced nitration of platelet proteins
Measurement of nitrotyrosine levels using a semi-quantita-
tive ELISA demonstrated the presence of low amounts of
nitrated proteins in both cytosolic and membrane fractions
of unstimulated platelets. The subsequent addition of peroxy-
nitrite (3 WM) led to a signi¢cant increase in nitrated platelet
proteins, but only of cytosolic proteins. In the cytosolic frac-
tion, peroxynitrite increased nitrotyrosine levels from a basal
level of 0.3 þ 0.1 to 6.4 þ 2.8 nmol NT-BSA equivalents/mg
protein (P6 0.01), whereas in the membrane fraction the in-
crease in nitration was not signi¢cant.
The inhibition of platelet aggregation by peroxynitrite (Fig.
1) was reversible, and therefore if protein nitration was a
regulator of platelet function, this too would be reversible.
After a 1 min incubation, peroxynitrite (3 WM) formed
6.4 þ 2.8 NT-BSA equivalents/mg protein in the cytosolic frac-
tion. The amount of nitrotyrosine fell, by 60 min, to 3.1 þ 0.9
NT-BSA equivalents/mg protein (Ps 0.05 compared to levels
after 1 min) and, after 90 min, the concentration was only
1.2 þ 0.4 NT-BSA equivalents/mg protein (P6 0.01; Fig. 2).
We also observed considerable variations between individual
platelet preparations in both the initial levels of nitration and
in the speed of the loss of nitration. In these experiments, the
low levels of nitrotyrosine in the membrane fraction did not
increase and remained constant over 90 min.
3.4. In£uence of peroxynitrite on thrombin-stimulated
protein phosphorylation
Previously, it had been shown that peroxynitrite (at high
concentrations above 150 WM) caused both nitration and
phosphorylation of proteins in platelets [20]. WPs were incu-
bated with 10 WM peroxynitrite, for time intervals up to 60
min and the extent of protein nitration was determined by
Western blotting. The incubation of platelets with a range
of peroxynitrite concentrations resulted in increased nitration
of many di¡erent protein bands (Fig. 3A), whereas thrombin
Fig. 1. The in£uence of peroxynitrite on platelet aggregation as a
function of time. Peroxynitrite (5 WM) was added to platelets and
incubated for up to 1 h at 37‡C without stirring, before the addition
of thrombin (0.02 U/ml). Platelet aggregation was measured 3 min
after the addition of thrombin. Results are expressed as percent in-
hibition of aggregation and represent the mean þ S.E.M. of four in-
dependent experiments.
Fig. 2. The in£uence of time on peroxynitrite-induced nitration of
platelet proteins. Peroxynitrite (3 WM) was incubated with WPs for
up to 90 min at 37‡C without stirring. Aliquots were taken at vari-
ous time points before being cooled and sonicated. The platelets
were subsequently centrifuged at 1500Ug for 5 min to separate the
membrane (a) and cytosolic fractions (b). The membrane fraction
was solubilised using CHAPS bu¡er (0.1%). Nitrotyrosine was then
measured in the membrane and cytosolic samples using a semi-
quantitative ELISA. Results are expressed as nmol NT-BSA equiva-
lents/mg protein and represent the mean þ S.E.M. of ¢ve independ-
ent experiments.
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alone produced little nitration. Interestingly, the combination
of peroxynitrite, followed by thrombin 1 min later, appeared
to enhance the nitration; again the extent of nitration of most
of the protein bands decreased markedly after 60 min, even
after addition of thrombin at each interval.
To assess the in£uence on platelet-signalling proteins, WPs
were incubated with peroxynitrite for time intervals up to 60
min before stimulation with thrombin (0.02 U/ml), and pro-
tein phosphorylation assessed by Western blotting. Thrombin
stimulation of platelets increased phosphorylation over a
broad range of protein sizes compared to unstimulated cells
(Fig. 3B). Incubation of platelets with peroxynitrite (10 WM)
for 1 min prior to thrombin stimulation led to a decrease in
phosphorylation of proteins with apparent molecular weights
of 72, 94 and 112 kDa. However, this inhibitory e¡ect of
peroxynitrite on the phosphorylation of some proteins was
reversible. The thrombin-induced phosphorylation of the 72
kDa protein, subsequently identi¢ed as syk (results not
shown), was strongly diminished by a 1 min pre-incubation
of the platelets with peroxynitrite. However, if the cells were
left to recover for 15 min after peroxynitrite, thrombin-stimu-
lated phosphorylation returned to control levels. Similarly,
phosphorylation of the 112 kDa began to recover within 15
min and was fully phosphorylated after 60 min, while the
thrombin-stimulated phosphorylation of the 94 kDa was still
only partial 60 min after peroxynitrite treatment. These data
suggest that peroxynitrite at low concentrations inhibits pro-
tein phosphorylation of speci¢c proteins, and that the mech-
anism is reversible in some cases. Immunoblotting experi-
ments did not reveal any nitrated proteins with the same
molecular weight as syk, indicating that syk may not be ni-
trated by peroxynitrite or thrombin (Fig. 3A).
In contrast, peroxynitrite was able to increase the tyrosine
phosphorylation of certain proteins. After 1 min of peroxyni-
trite treatment, increased levels of protein phosphorylation
were observed in the 35 and 38 kDa proteins in the presence
or absence of thrombin, and to a greater extent than with
thrombin alone (Fig. 3B). However, these e¡ects were transi-
ent, since they returned to levels seen with thrombin alone 15
min after addition of peroxynitrite. As shown many times
before, the src group of proteins was phosphorylated even
in the resting platelets and this was not changed by addition
of peroxynitrite. The level of phosphorylation of a 64 kDa
protein was reduced by thrombin; the signi¢cance of this is
unknown.
4. Discussion
The in£uence of peroxynitrite on platelet function has been
studied previously, but the results have been contradictory. In
earlier studies, peroxynitrite at concentrations above 150 WM
was shown to stimulate platelet aggregation in plasma-free
platelet preparations [5,6], while only in the presence of plas-
ma did it act as a platelet inhibitor [5,6]. The inhibitory e¡ect
of peroxynitrite was attributed to the formation of nitroso-
thiols, which act as NO donors and therefore inhibit platelets
via the stimulation of sGC. Indeed, in the presence of gluta-
thione, peroxynitrite does activate sGC [21]. We tested the
role of sGC in peroxynitrite-mediated inhibition using much
lower concentrations of the oxidant. At 1^10 WM, peroxyni-
trite was a potent inhibitor of platelets, but only a modest
activator of sGC compared to authentic NO (1 WM). Further-
more, peroxynitrite still inhibited platelets that had been ex-
posed to the sGC inhibitor ODQ, which was shown to be
active even after addition of low concentrations of peroxyni-
trite. Therefore, the data indicate that the inhibition of plate-
lets by peroxynitrite occurs by a process in which cGMP plays
only a minor part. This is reminiscent of our recent work in
which a synergistic inhibition of very low concentrations of
NO and hydrogen peroxide did not appear to require elevated
concentrations of cGMP [22]. However, in this case, a basal
concentration of cGMP was required because the inhibition
was blocked by ODQ [22].
The inhibition of platelets by peroxynitrite was fully revers-
ible, indicating that this was not simply a destructive e¡ect of
Fig. 3. A: The e¡ect of peroxynitrite on the nitration of platelet
proteins. WPs were treated with peroxynitrite (10 WM) for up to 60
min before the addition of thrombin (0.02 U/ml), and then incu-
bated for 1 min with stirring at 37‡C. Platelets were lysed with Nu-
PAGE sample bu¡er and subjected to SDS^PAGE using a Nu-
PAGE 4^12% gradient gel. The separated proteins were transferred
onto nitrocellulose membrane and then probed with anti-nitrotyro-
sine antibody (1:500). The antigen was visualised using the ECL
system. Lane 1: basal, 2: peroxynitrite 10 WM (1 min), 3: thrombin
0.02 U/ml, 4: peroxynitrite (1 min)+thrombin 0.02 U/ml, 5: peroxy-
nitrite (15 min)+thrombin 0.02 U/ml, 6: peroxynitrite (30 min)+-
thrombin 0.02 U/ml, 7: peroxynitrite (60 min)+thrombin 0.02 U/ml.
Each well contained 20 Wg platelet protein. The blot is a representa-
tive of four separate experiments. B: The in£uence of peroxynitrite
on the phosphorylation of platelet proteins. WPs were treated with
peroxynitrite (10 WM) for up to 60 min before the addition of
thrombin (0.02 U/ml), and then incubated for 1 min with stirring at
37‡C. Platelets were lysed with NuPAGE sample bu¡er and sub-
jected to SDS^PAGE using a NuPAGE 4^12% gradient gel. The
separated proteins were transferred onto nitrocellulose membrane
and then probed with anti-phosphotyrosine antibody (1:5000). The
antigen was visualised using the ECL system. Lane 1: basal, 2: per-
oxynitrite 10 WM (1 min), 3: thrombin 0.02 U/ml, 4: peroxynitrite
(1 min)+thrombin 0.02 U/ml, 5: peroxynitrite (15 min)+thrombin
0.02 U/ml, 6: peroxynitrite (30 min)+thrombin 0.02 U/ml, 7: per-
oxynitrite (60 min)+thrombin 0.02 U/ml. Each well contained 20 Wg
platelet protein. The blot is a representative of four separate experi-
ments.
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the oxidant on platelet proteins and lipids. The recovery oc-
curred within 30 min and was 70% recovered after 15 min
after addition of 5 WM peroxynitrite (Fig. 1). An alternative
explanation of a role for cGMP is that the inhibition of plate-
lets is due to the nitration of platelet proteins by the forma-
tion of nitrotyrosine. Nitration did occur, even at low concen-
trations of peroxynitrite and the extent of nitration increased
signi¢cantly at concentrations immediately above the IC50, as
detected by the ELISA. This increase occurred primarily in
the soluble fraction, suggesting that the nitrating species
passed through the membrane into the cytosol; this has
been reported in red blood cells [23]. The extent of the cyto-
solic nitration also diminished after a period of 1 h, which was
slightly longer than the recovery of the platelets in terms of
their response to thrombin. There was a signi¢cant variation
in the rate of loss of nitrated proteins in platelets from indi-
vidual donors. Nitrotyrosine is stable and its direct reversion
to tyrosine seems unlikely, although an intermediate non-en-
zymatic reduction to amines in tissues has been proposed [24].
The alternative would be proteolysis of the modi¢ed proteins
or further modi¢cation of the nitro group. Certainly, a recent
study has demonstrated that protein nitration enhances the
susceptibility to proteolytic cleavage by proteasomes [25].
However, there appear to be no reports of proteasomal activ-
ity in platelets although they do contain lysosomes. Further
work is required to establish the mechanism of nitrotyrosine
disappearance.
The stimulation of platelets results in the activation of sev-
eral key tyrosine kinases and phosphatases, leading to the
phosphorylation of several key cellular proteins [26]. The
events occur very early in the activation response and are
critical to further cellular activation and aggregation. There-
fore, it is possible that peroxynitrite inhibited platelet aggre-
gation through the nitration of key signalling proteins which
are normally phosphorylated during activation. We have
shown that pre-treatment of platelets with peroxynitrite inhib-
ited thrombin-induced phosphorylation of several proteins,
but not of others. These results may indicate that peroxyni-
trite inhibits platelet activation through the temporary impair-
ment of tyrosine phosphorylation of speci¢c signalling pro-
teins. Implicit in this mechanism is the question of whether
the reversibility of platelet inhibition and protein nitration,
following exposure to peroxynitrite, is associated with a re-
covery of platelet responsiveness to thrombin-induced tyrosine
phosphorylation of speci¢c proteins. Thrombin-induced phos-
phorylation of several proteins was lost, including syk, after a
1 min pre-incubation with peroxynitrite. However, the phos-
phorylation returned within 15^30 min of exposure to the
oxidant; this correlated temporally very well with the recovery
of aggregation response. The rate of recovery for phosphory-
lation was di¡erent for individual proteins, and not all pro-
teins fully recovered. This is new evidence that the e¡ect of
peroxynitrite on tyrosine phosphorylation is reversible. In oth-
er studies, the recovery may be blocked due to damage caused
by excessive nitration and oxidation of sulphydryl groups by
the use of peroxynitrite at concentrations of up to 1 mM
peroxynitrite. In one study in platelets, accumulative concen-
trations up to 800 WM peroxynitrite were used and no reversal
of the high levels of nitration were observed over 60 min [20].
An obvious mechanism for this inhibition may be that ni-
tration of the same tyrosine residue blocks its phosphoryla-
tion. However, no correlation existed between the inhibition
of tyrosine phosphorylation and the increase in nitration, and
subsequent changes occurring during the hour period. We
have been unable to demonstrate that proteins such as syk
are nitrated by peroxynitrite and, therefore, the reduction in
phosphorylation is likely to be due to the inhibition of anoth-
er protein kinase upstream from syk. In neuroblastoma cells,
the inhibition of tyrosine phosphorylation is associated with
compromised phosphoinositide signalling [27], an event cru-
cial for platelet function. The loss of nitro groups from spe-
ci¢c proteins, in a short time frame, may be a key event in
restoring platelet sensitivity to agonists. Non-speci¢c nitration
of proteins may not be important, except when exposed to
excess peroxynitrite. Therefore, partial loss of nitrated pro-
teins, or selective loss of nitro groups may be su⁄cient to
reverse the inhibition of platelet function.
Peroxynitrite enhanced the phosphorylation of proteins to a
greater extent than did thrombin, in particular those at 35 and
38 kDa; the latter co-migrates with p38 MAP kinase, which
his known to be activated by peroxynitrite [28]. Conversely,
some proteins are phosphorylated only after addition of
thrombin and not by peroxynitrite (e.g. 68 kDa protein).
The peroxynitrite-induced protein phosphorylation was tran-
sient and diminished after 15 min. There is no evidence that
they are directly related to protein nitration and again may be
due to activation of kinase upstream of these signalling pro-
teins. There are several mechanisms by which peroxynitrite
has been proposed to increase tyrosine phosphorylation.
These include the inhibition of speci¢c phosphatases [29], di-
rect activation of proteins kinases [30] or via the activation of
speci¢c tyrosine kinase receptors [31]. The precise molecular
relationship between protein nitration and phosphorylation in
platelets remains to be determined, but it is clearly indirect.
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